VRCA - Positive Top-line Phase 3 Trial Results could Propel Listing to Refill Recent Gap

2023-12-15 11:03:39 ET

DENVER, Colo., Dec 15, 2023 ( www.247marketnews.com )- Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) has been marching higher, since reporting, this morning, that its development and commercialization partner, Torii Pharmaceutical, reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of Molluscum Contagiosum (“molluscum”) in Japan.

Verrica is trading at $5.42, up $1.66 (+44.11%), on 16.6M shares traded.

Its 52-week range is $2.33 to $8.695. If this breaks today’s $6.20 high it has a very good chance of hitting $7 on a gap refill.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but …

The post Positive Top-line Phase 3 Trial Results could Propel Listing to Refill Recent Gap appeared first on 24/7 Market News .

For further details see: